CellaVision AB Interim report: January - March 2012
(Thomson Reuters ONE) -
More than 30 percent growth and doubled profit
January 1 - March 31, 2012
* Net sales rose by 32 % to SEK 40.4 million (30.6)
* The operating result was SEK 5.4 million (2.5)
* Profit before tax was SEK 4.4 million (0.3)
* Earnings per share were SEK 0.11 (0.00)
* Cash and cash equivalents at the end of the quarter were SEK 56.5 million
(40.2)
* CellaVision launched a blood analysis system for the veterinary market in
North America
CellaVision in brief
(SEK million) Jan-March 2012 Jan-March 2011 Full year 2011
Net sales 40.4 30.6 155.4
Gross profit 27.1 20.8 101.4
Operating result 5.4 2.5 17.8
Operating margin, % 13.4 8.2 11.5
Profit before tax 4.4 0.3 18.5
Cash flow -0.3 4.4 21.0
CEO Yvonne Mårtensson comments: Stronger quarter than expected
"We have a strong start to the year, with somewhat higher sales than we had
foreseen. During the period cooperation with our partners in Europe and North
America developed well and we see a continued strong underlying demand for our
products.
During the quarter we worked further for continued international market
expansion and product development. We have strengthened our presence in China by
establishing a market office in Shanghai and recruiting of local employees has
been started to give support to our partners. The venture will give us increased
understanding of the Chinese market and increase our visibility, which creates
interest for our products. China is a market with great long-term potential and
demand for our products should now be able to gradually gain momentum.
In February our technology efforts resulted in the introduction of an analyzer
for the veterinary market in the USA and Canada. There is interest in the
product mainly among large veterinary laboratories with high test sample volumes
and automation needs.
After the strong start to the year I have a positive view of CellaVision's
continued development in 2012, but do not yet regard the strong growth and level
of profitability as a trend for the full year."
Yvonne Mårtensson, CEO, CellaVision AB
For more information, please contact:
Yvonne Mårtensson, CEO Mobil: +46 708 33 77 82, email:
yvonne.martensson(at)cellavision.se
Johan Wennerholm, CFO Mobil: +46 708 33 81 68, email:
johan.wennerholm(at)cellavision.se
CellaVision Interim Report: January ? March 2012:
http://hugin.info/132164/R/1605642/508597.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1605642]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.04.2012 - 02:31 Uhr
Sprache: Deutsch
News-ID 1106888
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Lund
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 53 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision AB Interim report: January - March 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
